Based on prior models on the temporal evolution of AD biomarkers (Jack and Holtzman, 2013), Figure 4 summarizes a hypothetical model based on the key findings of CSF sTREM2- and sTNFR2 relationships to Aβ and tau levels in the different stages of AD, plotting biomarker severity (degree of abnormality) vs. disease stage. The gene discussed is MAPT; the disease is Alzheimer disease.